IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Mankind Pharma and Innovent Biologics Partner to Launch Groundbreaking PD-1 Immunotherapy in India

Duchenne Muscular Dystrophy: Diagnosis, Treatment, and Emerging Therapies

Ikena Oncology and Inmagene Biopharmaceuticals Announce Merger to Form ImageneBio

Fujirebio and Eisai Partner to Advance Diagnostics for Neurodegenerative Diseases

European Commission Approves Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H or dMMR mCRC

Home
/
update
/
details

ICGA Launches India's First Open-Access Cancer Data Portal to Advance Personalized Treatment

NextEdge Admin

22 Sep 2024

2 min 16 sec

The Indian Cancer Genome Atlas (ICGA) has launched a groundbreaking cancer data portal, providing open access to crucial information from Indian cancer patients. This resource is designed to support researchers and clinicians in developing personalized treatment strategies tailored to India's unique population. Initially, the platform includes data from 50 breast cancer patients, with plans to expand to over 500 within a year.

Operated by the ICGA Foundation, a not-for-profit organization, this initiative is supported by over 50 clinicians, researchers, and data analysts, aligning with India’s PRIDE guidelines that promote ethical collaboration in cancer research. Historically, cancer treatments in India have relied on Western data, which may not account for the molecular differences in Indian patients. The ICGA’s mission is to create India-specific datasets, facilitating the development of personalized therapies.

The portal is India's first to provide comprehensive multi-omics data, encompassing DNA, RNA, and protein profiles integrated with clinical outcomes. Experts like Professor Shekhar C Mande from Savitribai Phule Pune University highlight the portal’s potential to accelerate scientific discoveries and improve patient outcomes.

Global leaders, including Dr JC Zenklusen of The Cancer Genome Atlas (USA) and Professor Sunil Badve of Georgia University, urge others to contribute to this initiative. Dr Anand Deshpande, Non-Executive Director at ICGA, emphasized the importance of tailoring treatments to India’s genetic and environmental factors, calling for collective efforts to combat cancer through this revolutionary platform.